Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES)

Table 4 Comorbid Conditions According to Hyperpolypharmacy

Variable	All	No HPP	HPP	P-value
Comorbidity Count, mean (SD)	4.7 (2.0)	4.3 (1.8)	5.9 (2.1)	<0.001
Hypertension, %	76	74	83	0.04
Hypercholesterolemia, %	66	63	73	0.03
Myocardial Infarction, %	46	43	52	0.07
Coronary Artery Disease, %	40	35	54	<0.001
Stroke, %	22	20	27	0.05
Diabetes, %	39	32	59	<0.001
Asthma, %	17	13	28	0.001
Chronic Bronchitis, %	12	9	20	0.003
Emphysema, %	13	10	22	<0.001
Cancer, %	27	27	25	0.70
Anemia, %	12	11	15	0.20
CKD, %	14	10	24	<0.001
Dialysis, %	2	2	3	0.60
Thyroid disease, %	18	15	26	0.002
Arthritis, %	63	58	76	0.001
Liver disease, %	4	4	5	0.42

Abbreviations: HPP Hyperpolypharmacy, CI Confidence Interval, CKD Chronic Kidney Disease, SD standard deviation

ISSN: 1471-2261